key: cord-0693824-mxg7n77v
authors: Nguyen, Truc Ly; Lee, Youngho; Kim, Heebal
title: Immunogenic Epitope-Based Vaccine Prediction from Surface Glycoprotein of MERS-CoV by Deploying Immunoinformatics Approach
date: 2022-03-16
journal: Int J Pept Res Ther
DOI: 10.1007/s10989-022-10382-5
sha: 547c870228ea8f33498296ad596d7bdc928f8ae2
doc_id: 693824
cord_uid: mxg7n77v

Middle East respiratory syndrome coronavirus (MERS-CoV) has caused a high mortality rate since its emergence in 2012 in the Middle East. Currently, no effective drug or vaccine is available for MERS-CoV. Supportive care and prevention are the only ways to manage infection. In this study, we identified an epitope-based vaccine that could be an optimal solution for the prevention of MERS-CoV infection. By deploying an immunoinformatics approach, we predicted a subunit vaccine based on the surface glycoprotein (S protein) of MERS-CoV. For this purpose, the proteome of the MERS-CoV spike protein was obtained from the NCBI GenBank database. Then, it was subjected to a check for allergenicity using the Allergen FP v.1.0 tool. The Vaxijen v.2.0 tool was used to conduct antigenicity tests for binding with major histocompatibility complex class I and II molecules. The solidity of the predicted epitope-allele docked complex was evaluated by a molecular dynamics simulation. After docking a total of eight epitopes from the MERS-CoV S protein, further analyses predicted their non-toxicity and therapeutic immunogenic properties. These epitopes have potential utility as vaccine candidates against MERS-CoV, to be validated by wet-lab testing. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10989-022-10382-5.

Middle East respiratory syndrome coronavirus (MERS-CoV) has been identified as a novel human coronavirus that poses a major threat to global public health, calling for the urgent development of effective and safe vaccines. MERS-CoV is correlated with an unusually high death rate of almost 35% (Alqahtani et al. 2018; Bermingham et al. 2012; Zaki et al. 2012 ). The first known infections of MERS-CoV were detected in Saudi Arabia in 2012, and the virus later spread to other countries. Worldwide, 27 countries have reported cases since 2012. In the Western Pacific Region, countries that have experienced imported cases of MERS include China, Malaysia, the Philippines, and the Republic of Korea. The importation of the virus into the Republic of Korea in 2015 led to the largest MERS outbreak outside of the Middle East. This outbreak resulted in 186 laboratoryconfirmed cases and 36 deaths (Durai et al. 2015; Ki 2015) .

MERS-CoV was determined to be different from all other coronavirus strains that have been found in humans, including the severe acute respiratory syndrome coronavirus (SARS-CoV) and SARS-CoV-2 strains that caused the SARS (LeDuc and Barry 2004) and coronavirus disease 2019 (COVID-19) epidemics, respectively. So far, various types of vaccines targeting SARS-CoV and SARS-CoV-2 have been developed and tested in preclinical models. These include protein subunit vaccines, virus-like particle vaccines, DNA vaccines, RNA vaccines, viral vector vaccines, inactivated whole-virus vaccines, and live-attenuated virus vaccines Folegatti et al. 2020;  1 3 Jackson et al. 2020; Keech et al. 2020; Logunov et al. 2020; Mulligan et al. 2020; Sahin et al. 2020; Walsh et al. 2020; Zhu, et al. 2020a, b; Zhu, et al. 2020a, b) . However, only DNA-and viral vector-based vaccine candidates have been tested in preclinical models for MERS-CoV (Modjarrad et al. 2019; Xia et al. 2020 Xia et al. , 2021 .

In recent studies, epitope-based vaccine candidates were successfully developed against SARS-CoV-2, human cytomegalovirus, Tropheryma whipplei, nervous necrosis virus, candida fungus, and dengue virus (Akhtar et al. 2021a, b, c; Sunil Krishnan et al. 2020; Jain et al. 2021; Krishnan et al. 2021) . Subunit vaccines have been clinically approved for use against pertussis, influenza, Streptococcus pneumoniae, and Haemophilus influenzae type b (Folegatti et al. 2020; Koch et al. 2020) . To our knowledge, such protein subunit vaccines are easy to produce and relatively safe and well-tolerated compared to whole-virus vaccines and viral vector vaccines. They consist of viral antigenic fragments produced by recombinant protein techniques. Thus, our study predicted epitope-based vaccine peptides that have therapeutic properties against MERS-CoV, however, experimental evaluations remain necessary to verify the exact safety and immunogenicity profile of this vaccine.

The MERS-CoV surface glycoprotein (S protein) sequence was obtained from the National Center for Biotechnology Information (NCBI) database (http:// www. ncbi. nlm. nih. gov/) using the accession ID ALW82742.1. The experimentally derived 3D structure of the MERS-CoV S protein was retrieved from the Protein Data Bank (PDB ID: 5X59).

Using the online program ProtParam, the protein sequence was examined for chemical and physical characteristics such as grand average of hydropathicity (GRAVY), half-life, molecular weight, stability index, and amino acid atomic composition (Gasteiger et al. 2005 ).

The Vaxijen v.2.0 server (Doytchinova and Flower 2007;  http:// www. ddg-pharm fac. net/ vaxij en/ VaxiJ en/ VaxiJ en. html) was used to conduct antigenicity tests. For predicting allergenicity, the protein sequence was expanded for further analysis based on Allergen FP v.1.0. (Dimitrov et al. 2013 ).

B-cell epitopes were predicted using the free web server ABCpred (Saha and Raghava 2006 ; http:// crdd. osdd. net/ ragha va/ abcpr ed/). The criteria were established at 75% specificity, and 12-residue-long epitopes were deemed sufficient to induce a protective immune response. The top results ranked from 1 to 10 were considered.

Epitopes of cytotoxic T lymphocytes (CTLs) are important in vaccine development. Most importantly, it saves money and time as compared to wet-lab studies. Thus, CTL epitopes of target proteins of major histocompatibility complex (MHC) classes I and II were predicted using two different internet tools, the NetMHCpan 4.1 (http:// www. cbs. dtu. dk/ servi ces/ NetMH Cpan-4. 1/) and NetMHCIIpan 4.0 servers (http:// www. cbs. dtu. dk/ servi ces/ NetMH CIIpan-4.0/; Reynisson et al. 2020) . Because these techniques consider a large number of human leukocyte antigen (HLA) alleles during calculation, the results are highly significant. All alleles were chosen for prediction and the sequence was supplied in a simple format.

After finalizing the epitopes of both MHC class I and class II alleles, the ToxinPred server (Gupta et al. 2013 ) was used for in silico analysis to differentiate non-toxic and toxic peptides (http:// crdd. osdd. net/ ragha va/ toxin pred/). Only non-toxic epitopes were chosen for further investigation.

The 3D structures of HLA alleles were retrieved from the Research Collaboratory for Structural Bioinformatics PDB (RCSB PDB) database (Berman 2000) , and used for subsequent molecular docking purposes. The PatchDock server (Duhovny et al. 2002; Schneidman-Duhovny et al. 2005a, b) was used for conducting docking experiments (https:// bioin fo3d. cs. tau. ac. il/ Patch Dock/ php. php). Thereafter, the Fire-Dock server (Mashiach et al. 2008 ) was used to screen the best-docked results based on atomic contact energy (ACE; https:// bioin fo3d. cs. tau. ac. il/ FireD ock/ php. php).

The MDWeb tool (Hospital et al. 2012 ) was deployed for conducting molecular dynamics and simulation studies for obtaining the best-docked complexes (https:// mmb. irbba rcelo na. org/ MDWeb/). Trajectory analysis produced rootmean-square deviation (RMSD) and B-Factor plots that demonstrated the integrity and stability of complexes under simulated environments.

From the protein sequence of the MERS-CoV S protein, various physicochemical properties were computed using ProtParam. AllergenFP v.1.0 results indicated that the protein had non-allergenic properties as it held a higher Tanimoto similarity index of 0.84. Vaxijen v.2.0 analysis with a threshold of 0.4 revealed an antigenicity of 0.4829, indicating that the sequence was a probable antigen. Thus, we confirmed that the MERS-CoV S protein sequence can well be considered for epitope prediction. The abovementioned properties are summarized in Table 1 .

T-cell epitopes were predicted from the S protein using the NetMHCpan 4.1 server for MHC Class I HLA proteins and the NetMHCIIpan 4.0 server for MHC Class II HLA proteins as both servers work efficiently based on an artificial neural network schematic framework. Tables S1 and S2 present the screened epitopes based on the binding affinity and rank generated by the NetMHC servers. Supplementary Excel Sheets 1 and 2 present the full T-cell epitopes for both MHC I and MHC II HLA allelic determinants.

The ABCpred tool was deployed for B-cell epitope prediction. B-cell epitopes bind to B-cell receptors (BCRs) and induce immune responses against MERS-CoV. Along with T-cell epitopes, B-cell epitopes are highly useful in generating immunogenicity (Table S3 ).

Allergenicity prediction using AllergenFP v.1.0 revealed that the complete S protein sequence represented a probable non-allergen. Vaxijen v.2.0 analysis of T-cell and B-cell epitopes from the MERS-CoV S protein using a threshold of 1.1 facilitated the screening of epitopes of high antigenicity, indicating that the selected protein had probable antigenic and immunogenic properties. Thus, we confirmed that the protein sequence can be considered for epitope prediction. After this analysis, the screened epitopes were analyzed using the ToxinPred tool that further confirmed their nontoxic features (Table 2) .

All receptor structures were retrieved from the RCSB PDB database. The structural files for MHC class II HLA DRB1:0101 (PDB ID: 1AQD), MHC Class I HLA-A*0101 

Molecular docking studies were conducted using the Patch-Dock and FireDock tools (Dina Schneidman- Duhovny et al. 2005a, b) . Figure 1 presents all 11 docked complexes, of which eight complexes had suitable ACE values from − 9 to − 5 kcal/mol . The eight selected complexes are presented in Table 3 . The obtained results also indicated perfect binding between the ligand and receptor as presented in Fig. 2 . Two B-cell epitopes, LEPRSGNHCPAG and QNCTAVG-VRQQR, bound to the BCR_FAB domain during molecular docking and showed chemical interactions in visualizations with PyMOL.

Similarly, the T-cell epitopes GRGVFQNCTAVGVRQ and EGGGWLVASGSTVAM interacted with MHC class II HLA determinants ( Fig. 3A and B) . Additionally, the T-cell epitopes YSNITITYQGLF, YIDLKELGNYTY, SYIDLKELGNYT, and PTNFSFGVTQEY were observed to interact with MHC class I HLA determinants (Fig. 3C-F ). All such T-cell epitope interactions were observed in the binding pocket of core protein receptors using the PyMOL visualization tool.

For epitopes interacting with the HLA allele structures, the RMSD values and atomic fluctuation per amino acid residue were acquired, allowing for ideal pair selection and confirmation. The MDWeb tool was deployed for this purpose, and RMSD and B-factor values in the appropriate range were successfully obtained (Sunil Krishnan et al. 2020) . The RMSD and B-factor plots of the B-cell epitope with the lowest ACE value interacting with the BCR_FAB domain are indicated in Fig. 4 . Figures 5 and 6 present RMSD and B-factor plots, respectively, for all T-cell epitopes interacting with MHC class I and class II HLA determinants. The obtained results indicated perfect molecular stability in the docked complex in short-run simulations using the MDWeb tool.

MERS-CoV and SARS-CoV-2 are emerging infectious viruses that are extremely harmful to humans. Effective immunization and protective measures against these infections are still largely undiscovered. Gaps in our understanding of these pathogens' protective immunity pose challenges to vaccine development (Sunil Krishnan et al. 2020; Park et al. 2019) .

This study aimed to use immunoinformatics approach to screen of vaccine epitopes to identify the most antigenic protein of MERS-CoV as well as the B-and T-cell epitopes that map onto this protein. The immunoinformatics method, which is based on bioinformatics breakthroughs, is a viable and necessary tool for developing vaccines against new, highly dangerous microorganisms. In this investigation, critical dominant immunogens were screened against MERS-CoV using an immunoinformatics-driven strategy.

The results revealed that the S protein was a superior antigenic protein. Indeed, all current MERS vaccination trials focus on the S protein of MERS-CoV, which facilitated the identification of the host cell DPP4 receptor and causes a strong immune response (Wang et al. 2013) . After docking a total of eight epitopes from the MERS-CoV S protein, (Akhtar et al. 2021a, b, c; Sunil Krishnan et al. 2020; Jain et al. 2021; Krishnan et al. 2021) . Thus, the identified T-cell and B-cell epitopes have therapeutic potential against the MERS virion. 

MERS-CoV causes a severe respiratory disorder, and better vaccines need to be developed to control this pathogen. The main target of this study was to identify peptide epitopes from MERS-CoV for both T cells and B cells that have therapeutic potential. Our modern in silico study demonstrates a fast strategy for vaccine development against MERS-CoV that nevertheless requires wet-lab testing for final validation. 

In-silico design of a multivalent epitope-based vaccine against Candida auris

Immuno-informatics quest against COVID-19/SARS-COV-2: determining putative T-cell epitopes for vaccine prediction

Design of a novel and potent multivalent epitope based human cytomegalovirus peptide vaccine: an immunoinformatics approach

Prevalence of comorbidities in cases of Middle East respiratory syndrome coronavirus: a retrospective study

Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults

The protein data bank

Severe respiratory illness caused by a novel coronavirus

AllergenFP: allergenicity prediction by descriptor fingerprints

VaxiJen: a server for prediction of protective antigens, tumour antigens and subunit vaccines

Efficient unbound docking of rigid molecules. Lecture notes in computer science

Middle East respiratory syndrome coronavirus: transmission, virology and therapeutic targeting to aid in outbreak control

Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial

Protein identification and analysis tools on the ExPASy server. The proteomics protocols handbook

In silico approach for predicting toxicity of peptides and proteins

MDWeb and MDMoby: an integrated web-based platform for molecular dynamics simulations

An mRNA vaccine against SARS-CoV-2-preliminary report

An immunoinformatics study: designing multivalent T-cell epitope vaccine against canine circovirus

In-silico proteomic exploratory quest: crafting T-cell epitope vaccine against Whipple's disease

Epitope based vaccine prediction for SARS-COV-2 by deploying immunoinformatics approach

Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine

MERS outbreak in Korea: hospital-to-hospital transmission

Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial

Immunoinformatics designed T cell multi epitope dengue peptide vaccine derived from non structural proteome

SARS, the first pandemic of the 21st century

Semikhin AS et al (2020) Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia

FireDock: a web server for fast interaction refinement in molecular docking

Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial

Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults

Generation and characterization of a monoclonal antibody against MERS-CoV targeting the spike protein using a synthetic peptide epitope-CpG-DNA-liposome complex

NetMH-Cpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data

Prediction of continuous B-cell epitopes in an antigen using recurrent neural network

COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses

PatchDock and SymmDock: servers for rigid and symmetric docking

PatchDock and SymmDock: servers for rigid and symmetric docking

T cell epitope designing for dengue peptide vaccine using docking and molecular simulation studies

Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates

Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4

Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial

Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia

Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial

Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial

The online version contains supplemen-